Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

BACKGROUND: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2− advanced breast cancer (ABC). OBJECTIVE: We assessed health-related quality of life (QoL) using patient-reported o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tibau, Ariadna, Martínez, M. Teresa, Ramos, Manuel, De La Cruz-Merino, Luis, Santaballa, Ana, O’Connor, Miriam, Martínez-Jañez, Noelia, Moreno, Fernando, Fernández, Isaura, Virizuela, Juan Antonio, Alarcón, Jesús, de La Haba-Rodríguez, Juan, Sánchez-Rovira, Pedro, Albacar, Cinta Rosa, Bueno Muiño, Coralia, Kelly, Catherine, Casas, Maribel, Bezares, Susana, Rosell, Libertad, Albanell, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893357/
https://www.ncbi.nlm.nih.gov/pubmed/36743520
http://dx.doi.org/10.1177/17588359221148921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893357/
https://www.ncbi.nlm.nih.gov/pubmed/36743520
http://dx.doi.org/10.1177/17588359221148921

Ejemplares similares